Affordable Access

deepdyve-link
Publisher Website

Costs of herpes zoster complications in older adults: A cohort study of US claims database.

Authors
  • Meyers, Juliana L1
  • Candrilli, Sean D2
  • Rausch, Debora A3
  • Yan, Songkai4
  • Patterson, Brandon J5
  • Levin, Myron J6
  • 1 RTI Health Solutions, Research Triangle Park, NC, United States. Electronic address: [email protected] , (United States)
  • 2 RTI Health Solutions, Research Triangle Park, NC, United States. Electronic address: [email protected] , (United States)
  • 3 GSK, Philadelphia, PA, United States. Electronic address: [email protected] , (United States)
  • 4 GSK, Philadelphia, PA, United States. Electronic address: [email protected] , (United States)
  • 5 GSK, Philadelphia, PA, United States. Electronic address: [email protected] , (United States)
  • 6 University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: [email protected] , (United States)
Type
Published Article
Journal
Vaccine
Publication Date
Feb 21, 2019
Volume
37
Issue
9
Pages
1235–1244
Identifiers
DOI: 10.1016/j.vaccine.2018.11.079
PMID: 30685248
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Herpes zoster (HZ) incidence increases with age, and the burden of HZ is expected to grow with aging of populations worldwide. We aim to determine the incremental healthcare resource utilization and associated costs of patients with common HZ-related complications other than postherpetic neuralgia (cutaneous, neurologic and ophthalmic) compared to uncomplicated HZ. We conducted a retrospective cohort study of commercial health insurance claims covering about 40 million immunocompetent individuals aged ≥50 years at study entry from all over the US, from 2008 to 2013, with follow-up for one year after HZ onset. All-cause healthcare resource utilization and direct healthcare costs were recorded and calculated from six months before until 12 months after HZ onset. The mean costs for HZ patients with complications were compared to the mean costs for patients with uncomplicated HZ. Multivariable regression analyses estimated mean incremental costs adjusted for demographics, comorbidities, type of complication and time period. Over the five-year study period, 22,948 HZ patients (60% women, median age 62 years) who experienced at least one of the selected complications were compared to 213,232 patients (63% women, median age 61 years) with uncomplicated HZ. Overall, the mean annual incremental unadjusted costs for the patients with HZ-related complications were US$4716, ranging from US$2173 for ophthalmic to US$18,323 for neurologic complications. Most of the incremental costs associated with HZ complications were accrued during the first quarter after HZ onset. For each complication type the incremental costs increased with age up to, but not including the oldest group, aged ≥80 years. Approximately 10% of immunocompetent older patients with HZ develop complications which considerably increase the economic burden of HZ. Vaccination of older adults will offset some of the burden of HZ, including costs associated with HZ-related complications. Copyright © 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.. All rights reserved.

Report this publication

Statistics

Seen <100 times